State In India Bans 57 Drugs As Substandard
This article was originally published in PharmAsia News
Executive Summary
The Indian state of Uttar Pradesh banned 57 drugs made by 39 separate companies as substandard after tests were conducted, according to the director of the Health Department. The department's director ordered chief medical officers to seize all stocks of the drugs in the state. The state also suspended the licenses of 27 medical stores. (Click here for more
You may also be interested in...
Sanofi Clinches Key Phase III Immunology Win With Rilzabrutinib
Sanofi’s BTK inhibitor – one of two from its 2021 Principia buy – passed a Phase III test in immune thrombocytopenia as the company focuses on Dupixent-like blockbusters going forward.
US FDA Gene Therapy Accelerated Approval Guidance Will Describe ‘Buckets’ Of Use Scenarios
Forthcoming guidance is expected to describe areas of “low-hanging fruit” and those that are more challenging for use of the expedited pathway, Center for Biologics Evaluation and Research Director Peter Marks said.
FTC Early Findings In PBM Investigation Coming By Mid-Summer, Chair Kahn Says
The agency is also poised to announce another development in its scrutiny of the drug patents listed in the FDA’s Orange Book.